NextCell Pharma AB
65G
Company Profile
Business description
NextCell Pharma AB is a healthcare services provider. The company is engaged in the research of stem cell and is developing the candidate drug ProTrans for the treatment of diabetes and immunosuppression in kidney transplants.
Contact
Karolinska Institutet Science Park
Halsovagen 7
Huddinge14157
SWET: +46 87355595
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
24
Stocks News & Analysis
stocks
The ASX data center stock flying under the radar
While markets chase AI hype, this data centre company offers real data center earnings and a visible growth pipeline.
stocks
What did Morningstar subscribers buy and sell during June?
ETFs took centre stage in June alongside renewed interest in beaten down growth names.
stocks
Australia’s largest gold miner downgraded on a falling gold price
A cooling gold price sees fair value cuts across the board.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,035.40 | 15.20 | -0.17% |
| CAC 40 | 8,366.85 | 2.20 | 0.03% |
| DAX 40 | 25,147.03 | 32.78 | 0.13% |
| Dow JONES (US) | 52,508.27 | 9.63 | 0.02% |
| FTSE 100 | 10,529.39 | 31.10 | 0.30% |
| HKSE | 24,714.28 | 373.55 | 1.53% |
| NASDAQ | 26,107.01 | 233.83 | 0.90% |
| Nikkei 225 | 68,410.74 | 667.24 | 0.98% |
| NZX 50 Index | 13,640.73 | 10.49 | -0.08% |
| S&P 500 | 7,543.59 | 28.25 | 0.38% |
| S&P/ASX 200 | 8,840.10 | 16.90 | -0.19% |
| SSE Composite Index | 3,963.90 | 3.22 | -0.08% |